Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,944 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.
Pasnoor M, He J, Herbelin L, Burns TM, Nations S, Bril V, Wang AK, Elsheikh BH, Kissel JT, Saperstein D, Shaibani JA, Jackson C, Swenson A, Howard JF Jr, Goyal N, David W, Wicklund M, Pulley M, Becker M, Mozaffar T, Benatar M, Pazcuzzi R, Simpson E, Rosenfeld J, Dimachkie MM, Statland JM, Barohn RJ; Methotrexate in MG Investigators of the Muscle Study Group. Pasnoor M, et al. Among authors: jackson c. Neurology. 2016 Jul 5;87(1):57-64. doi: 10.1212/WNL.0000000000002795. Epub 2016 Jun 15. Neurology. 2016. PMID: 27306628 Free PMC article. Clinical Trial.
Phase II trial of methotrexate in myasthenia gravis.
Pasnoor M, He J, Herbelin L, Dimachkie M, Barohn RJ; Muscle Study Group. Pasnoor M, et al. Ann N Y Acad Sci. 2012 Dec;1275(1):23-8. doi: 10.1111/j.1749-6632.2012.06804.x. Ann N Y Acad Sci. 2012. PMID: 23278574 Free PMC article. Clinical Trial.
Leg amyotrophic diplegia: prevalence and pattern of weakness at US neuromuscular centers.
Dimachkie MM, Muzyka IM, Katz JS, Jackson C, Wang Y, McVey AL, Dick A, Pasnoor M, Mozaffar MT, Xiao-Song Z, Kissel JT, Ensrud E, Rosenfeld J, Barohn RJ. Dimachkie MM, et al. Among authors: jackson c. J Clin Neuromuscul Dis. 2013 Sep;15(1):7-12. doi: 10.1097/CND.0b013e31829e22d1. J Clin Neuromuscul Dis. 2013. PMID: 23965403 Free PMC article.
A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis.
Shefner JM, Cudkowicz ME, Hardiman O, Cockcroft BM, Lee JH, Malik FI, Meng L, Rudnicki SA, Wolff AA, Andrews JA; VITALITY-ALS Study Group. Shefner JM, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2019;0(0):1-11. doi: 10.1080/21678421.2019.1612922. Amyotroph Lateral Scler Frontotemporal Degener. 2019. PMID: 31081694 Clinical Trial.
Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS.
Benatar M, Zhang L, Wang L, Granit V, Statland J, Barohn R, Swenson A, Ravits J, Jackson C, Burns TM, Trivedi J, Pioro EP, Caress J, Katz J, McCauley JL, Rademakers R, Malaspina A, Ostrow LW, Wuu J; CReATe Consortium. Benatar M, et al. Among authors: jackson c. Neurology. 2020 Jul 7;95(1):e59-e69. doi: 10.1212/WNL.0000000000009559. Epub 2020 May 8. Neurology. 2020. PMID: 32385188 Free PMC article.
Clinical features of LRP4/agrin-antibody-positive myasthenia gravis: A multicenter study.
Rivner MH, Quarles BM, Pan JX, Yu Z, Howard JF Jr, Corse A, Dimachkie MM, Jackson C, Vu T, Small G, Lisak RP, Belsh J, Lee I, Nowak RJ, Baute V, Scelsa S, Fernandes JA, Simmons Z, Swenson A, Barohn R, Sanka RB, Gooch C, Ubogu E, Caress J, Pasnoor M, Xu H, Mei L. Rivner MH, et al. Among authors: jackson c. Muscle Nerve. 2020 Sep;62(3):333-343. doi: 10.1002/mus.26985. Epub 2020 Jun 10. Muscle Nerve. 2020. PMID: 32483837 Free PMC article.
A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS.
Shefner JM, Andrews JA, Genge A, Jackson C, Lechtzin N, Miller TM, Cockroft BM, Meng L, Wei J, Wolff AA, Malik FI, Bodkin C, Brooks BR, Caress J, Dionne A, Fee D, Goutman SA, Goyal NA, Hardiman O, Hayat G, Heiman-Patterson T, Heitzman D, Henderson RD, Johnston W, Karam C, Kiernan MC, Kolb SJ, Korngut L, Ladha S, Matte G, Mora JS, Needham M, Oskarsson B, Pattee GL, Pioro EP, Pulley M, Quan D, Rezania K, Schellenberg KL, Schultz D, Shoesmith C, Simmons Z, Statland J, Sultan S, Swenson A, Berg LHVD, Vu T, Vucic S, Weiss M, Whyte-Rayson A, Wymer J, Zinman L, Rudnicki SA. Shefner JM, et al. Among authors: jackson c. Amyotroph Lateral Scler Frontotemporal Degener. 2021 May;22(3-4):287-299. doi: 10.1080/21678421.2020.1822410. Epub 2020 Sep 24. Amyotroph Lateral Scler Frontotemporal Degener. 2021. PMID: 32969758 Free PMC article. Clinical Trial.
Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis.
Placek K, Benatar M, Wuu J, Rampersaud E, Hennessy L, Van Deerlin VM, Grossman M, Irwin DJ, Elman L, McCluskey L, Quinn C, Granit V, Statland JM, Burns TM, Ravits J, Swenson A, Katz J, Pioro EP, Jackson C, Caress J, So Y, Maiser S, Walk D, Lee EB, Trojanowski JQ, Cook P, Gee J, Sha J, Naj AC, Rademakers R; CReATe Consortium; Chen W, Wu G, Paul Taylor J, McMillan CT. Placek K, et al. Among authors: jackson c. EMBO Mol Med. 2021 Jan 11;13(1):e12595. doi: 10.15252/emmm.202012595. Epub 2020 Dec 3. EMBO Mol Med. 2021. PMID: 33270986 Free PMC article.
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Howard JF Jr, et al. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Lancet Neurol. 2021. PMID: 34146511 Clinical Trial.
4,944 results